Showing 1 to 1 of 1 results
dailymail.co.uk
🌐 90% Global Worthiness
Pembrolizumab Extends Head and Neck Cancer Remission by 30 Months
A global phase III trial involving 714 patients with newly diagnosed head and neck cancer showed that pembrolizumab combined with standard treatment significantly increased disease-free survival to 60 months compared to 30 months for standard treatment alone.
Pembrolizumab Extends Head and Neck Cancer Remission by 30 Months
A global phase III trial involving 714 patients with newly diagnosed head and neck cancer showed that pembrolizumab combined with standard treatment significantly increased disease-free survival to 60 months compared to 30 months for standard treatment alone.
Progress
40% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results